AD Biotech, Quest Pharma deal
The companies formed a JV to develop immunotherapies for cancer. The companies will work together to co-develop products that combine their technologies. Quest PharmaTech said the deal gives it access to AD Biotech's antibody, protein transduction domain and manufacturing technologies. Quest PharmaTech also said it will provide technical expertise to AD Biotech to assist with the development of AD Biotech's IgY antibody technology development.
Quest PharmaTech is combining immunotherapeutic antibodies with chemotherapy, immune-adjuvants and photodynamic therapy to develop compounds to treat cancer. The company received $2 million in clinical development funding from AD Biotech, which has agreed to provide up to an additional $10 million in exchange for common shares of Quest PharmaTech and a share of revenues of products. ...